Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care Center

European Journal of Endocrinology

Volumn 169, Issue 6, 2013, Pages 891-899

  Ayala Ramirez, Montserrat ^a   Jasim, Sina ^b   Feng, Lei ^c   Ejaz, Shamim ^a   Deniz, Ferhat ^a   Busaidy, Naifa ^a   Waguespack, Steven G ^a   Naing, Aung ^c   Sircar, Kanishka ^d   Wood, Christopher G ^c   Pagliaro, Lance ^c   Jimenez, Camilo ^a   Vassilopoulou Sellin, Rena ^a   Habra, Mouhammed Amir ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UTMDACC   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOTANE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL CARCINOMA; ENDOMETRIUM CARCINOMA; FAMILIAL CANCER; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; SENESCENCE; SKIN CANCER; TERTIARY HEALTH CARE; THYROID PAPILLARY CARCINOMA; UTERINE CERVIX CANCER; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; AGE; AGED; ALGORITHM; CANCER CENTER; DISEASE FREE SURVIVAL; DISEASE MANAGEMENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECRETION (PROCESS); STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGE FACTORS; AGED; ALGORITHMS; CANCER CARE FACILITIES; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TEXAS; TREATMENT OUTCOME;

EID: 84888267331     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0519     Document Type: Article

References (56)

1. Gerhardt PR, Handy VH & Ferber B. Trends in cancer incidence, mortality, and probability in the state of New York. New York State Journal of Medicine 1957 57 1387-1390.
2. Griswold MH & Cutler SJ. The Connecticut cancer register. Seventeen years of experience, 1956. Connecticut Medicine 2006 70 323-328.
3. Soreide JA, Brabrand K & Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World Journal of Surgery 1992 16 663-667 (discussion 668). (doi:10.1007/BF02067349)
4. Nader S, Hickey RC, Sellin RV & Samaan NA. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983 52 707-711. (doi:10.1002/1097-0142 (19830815) 52:4<707::AID-CNCR28 20520424>3.0. CO;2-N)
5. Vassilopoulou-Sellin R & Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001 92 1113-1121. (doi:10.1002/1097-0142 (20010901) 92:5<1113::AID-CNCR1428>3.0. CO;2-I)
6. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2650-2655. (doi:10.1210/jc.2005-2730)
7. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF & Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery 2001 25 891-897. (doi:10.1007/s00268-001-0047-y)
8. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV & Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. European Journal of Cancer 2013 2 S0959-8049 (13) 00173-1
9. Ramsay O. Malignant tumors of the suprarrenal glands. Bulletin of the Johns Hopkins Hospital 1899 94-96 20-29.
10. Hench PS, Kendall EC, Slocumb CH & Polley HF. The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (compound E) on the acute phase of rheumatic fever; preliminary report. Proceedings of the Staff Meetings. Mayo Clinic 1949 24 277-297.
11. Hutter AM Jr & Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o, p'DDD in 138 patients. American Journal of Medicine 1966 41 581-592. (doi:10.1016/0002-9343 (66) 90220-8)
12. Varley JM, McGown G, Thorncroft M, Cochrane S, Morrison P, Woll P, Kelsey AM, Mitchell EL, Boyle J, Birch JM et al. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 1996 12 2437-2442.
13. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991 66 589-600. (doi:10.1016/0092-8674 (81) 90021-0)
14. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail F, Jullian E, Gicquel C, Bertagna X et al. Mutations of b-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 2005 65 7622-7627.
15. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H et al. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nature Genetics 1996 14 171-173. (doi:10.1038/ng1096-171)
16. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP & Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 2559-2565. (doi:10.1210/jc.82.8.2559)
17. Weksberg R, Shen DR, Fei YL, Song QL & Squire J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nature Genetics 1993 5 143-150. (doi:10.1038/ng1093-143)
18. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and b-catenin. American Journal of Pathology 2012 181 1017-1033. (doi:10.1016/j.ajpath.2012.05.026)
19. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL & Sidhu SB. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer 2009 16 573-583. (doi:10.1677/ERC-08-0237)
20. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C & Lui WO. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-Related Cancer 2011 18 643-655. (doi:10.1530/ERC-11-0082)
21. De Lellis RA LR, Heitz PU & Eng C. Pathology and genetics of tumours of endocrine organs. In World Health Organization Classification of Tumours. IARC Press, 2004.
22. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 243-250. (doi:10.1002/cncr.24030)
23. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 2010 46 713-719. (doi:10.1016/j.ejca.2009.12.007)
24. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B et al. Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 2012 366 2189-2197. (doi:10.1056/NEJMoa1200966)
25. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF & Samaan NA. Adrenal cortical carcinoma. Cancer 1989 64 765-769. (doi:10.1002/1097-0142 (19890801) 64:3<765::AID-CNCR28 20640333>3.0. CO;2-I)
26. Pommier RF & Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992 112 963-970 (discussion 970-961).
27. Schulick RD & Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 1999 6 719-726. (doi:10.1007/s10434-999-0719-7)
28. Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, Burgess MA & Evans DB. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995 118 1090-1098. (doi:10.1016/S0039-6060 (05) 80119-9)
29. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 192-197. (doi:10.1210/jc.2012-2367)
30. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E & Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008 113 3130-3136. (doi:10.1002/cncr.23886)
31. Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, Kercher KW & Heniford BT. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006 140 914-920 (discussion 919-920). (doi:10.1016/j.surg.2006. 07.035)
32. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, Rowland C, Young WF Jr & van Heerden JA. Adrenocortical carcinoma: surgical progress or status quo? Archives of Surgery 2001 136 543-549. (doi:10.1001/archsurg. 136.5.543)
33. Shiloach M, Frencher SK Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh MG, Richards KE, Ko CY & Hall BL. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. Journal of the American College of Surgeons 2010 210 6-16. (doi:10.1016/j.jamcollsurg.2009.09.031)
34. Hutter MM, Rowell KS, Devaney LA, Sokal SM, Warshaw AL, Abbott WM & Hodin RA. Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. Journal of the American College of Surgeons 2006 203 618-624. (doi:10.1016/j.jamcollsurg.2006.07.010)
35. Beard CM, Yunginger JW, Reed CE, O'Connell EJ & Silverstein MD. Interobserver variability in medical record review: an epidemiological study of asthma. Journal of Clinical Epidemiology 1992 45 1013-1020. (doi:10.1016/0895- 4356 (92) 90117-6)
36. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT & Lee JE. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Annals of Surgical Oncology 2010 17 263-270. (doi:10.1245/s10434-009-0716-x)
37. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M & Worden FP. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005 12 667-680. (doi:10.1677/erc.1.01029)
38. Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE & Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surgical Endoscopy 2013 27 4026-4032. (doi:10.1007/s00464-013-3034-0)
39. Hermsen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, Nieveen van Dijkum EJ, Haak HR & Dutch Adrenal N. Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery 2012 152 50-56. (doi:10.1016/j.surg.2012.02.005)
40. Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Ali A, Paccotti P, Porpiglia F, Fontana D & Angeli A. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001 57 176-182. (doi:10.1016/S0090-4295 (00) 00852-9)
41. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP & Brennan MF. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology 2002 20 941-950. (doi:10.1200/JCO.20.4.941)
42. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, Ishidoya S, Arai Y et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal 2008 55 49-55. (doi:10.1507/endocrj. K07-079)
43. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS & Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of Surgical Oncology 2012 105 709-713. (doi:10.1002/jso.23015)
44. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J, Willenberg HS, Beuschlein F, Fottner C et al. The role of surgery in the management of recurrent adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 181-191. (doi:10.1210/jc.2012-2559)
45. Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997 122 1212-1218. (doi:10.1016/S0039-6060 (97) 90229-4)
46. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 1994 69 947-951. (doi:10.1038/bjc.1994.183)
47. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E et al. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372-2380. (doi:10.1056/NEJMoa063360)
48. Fareau GG, Lopez A, Stava C & Vassilopoulou-Sellin R. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 2008 19 637-644. (doi:10.1097/CAD. 0b013e328300542a)
49. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA & Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British Journal of Cancer 2013 108 826-830. (doi:10.1038/bjc.2013.46)
50. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, Kenn W, Hahner S, Allolio B & Flentje M. Radiotherapy in adrenocortical carcinoma. Cancer 2009 115 2816-2823. (doi:10.1002/cncr.24331)
51. Lack EE, Mulvihill JJ, Travis WD & Kozakewich HP. Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors. Pathology Annual 1992 27 1-53.
52. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM & Birch JM. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors American Journal of Human Genetics 1999 65 995-1006. (doi:10.1086/302575)
53. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Human Mutation 2003 21 313-320. (doi:10.1002/humu.10185)
54. Didolkar MS, Bescher RA, Elias EG & Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981 47 2153-2161. (doi:10.1002/1097-0142 (19810501) 47:9<2153::AID- CNCR2820470908> 3.0. CO;2-6)
55. Layde PM, Broste SK, Desbiens N, Follen M, Lynn J, Reding D & Vidaillet H. Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis. Journal of Clinical Epidemiology 1996 49 835-841. (doi:10.1016/0895-4356 (96) 00006-6)
56. Sutherland LR & Verhoef MJ. Patients who seek a second opinion: are they different from the typical referral? Journal of Clinical Gastroenterology 1989 11 308-313. (doi:10.1097/00004836-198906000-00013)